Nexstim Plc · OMXHEX:NXTMH
Nexstim — Redeye Life Science Day 2020
12 slides from Nexstim's conference presentation, Nov 26, 2020
Slide 1: Nexstim. Personalised depression treatment.
Nexstim. Personalised depression treatment. Mikko Karvinen| CEO | Nexstim Plc Nexstim Plc Corporate Presentation, Redeye Life Science Day 2020, Stockholm, 26PlcNovember 2020 Nexstim
Slide 2: Important Information
Important Information This document and the information contained herein are being presented by Nexstim Oyj other than the date of this presentation. Nothing contained herein is, or should be relied upon (“Nexstim” or the “Company”). In connection with any presentation or review of this document, as
Slide 3: Table of Contents
Table of Contents • Overview • Therapeutic ‒ Major Depressive Disorder (MDD) • Business Update & Key Financials Nexstim Plc Confidential Presentation 3
Slide 4: Nexstim has a unique proprietary neuronavigated TMS technology
Nexstim has a unique proprietary neuronavigated TMS technology that delivers best in class mapping and treatment for patients with brain diseases and disorders. We are well positioned to a disruptive shift in depression treatment and therapy delivery. With improving economics, driven by record reven
Slide 5: Personalised Transcranial Magnetic Stimulation (TMS) Overview
Personalised Transcranial Magnetic Stimulation (TMS) Overview SmartFocus® Technology with a Highly Sophisticated 3D Navigation • Commercial-stage med tech company with a unique, proprietary Unique & Proprietary navigated neuro-stimulation technology for diagnostic and Technology therapeutic applicat
Slide 6: Proprietary Navigated TMS System Overview
Proprietary Navigated TMS System Overview Only TMS technology with ability to take the uniqueness of a patient’s brain into consideration for therapeutic and diagnostic applications Commercial Use System Application Europe US Status FDA approved with Multiple systems Depression CE marked existing in
Slide 7: NBT® for Depression
NBT® for Depression Therapeutic Nexstim depression business opportunity Market size estimate2 (patients) • Major depressive disorder affects 2-5% of the population in People affected by MDD globally developed countries1 216m Patients not responding to medicines • Existing psychotherapy and pharmacol
Slide 8: Nexstim Business Update H1 2020
Nexstim Business Update H1 2020 Business Operations • Focused on minimizing the effect of COVID-19 pandemic as well as updating Company strategy • Strong progress considering the difficult business environment ‒ Four new NBS systems sold (three in the US and one in Europe) ‒ Total of five new NBT® s
Slide 9: NBT® / NBS Revenue – Existing Business
NBT® / NBS Revenue – Existing BusinessCumulative YTD Total Revenue 2018-2020 Business Operations 4 000 000 € 3 500 000 € • Steadily growing business, showing all time high 3 000 000 € figures in H1 2020 2 500 000 € • Rolling 12 months revenue has been staying well 2 000 000 € above the growing trend
Slide 10: Near-term Objectives / Milestones
Near-term Objectives / Milestones Business Operations Decrease the operating loss with focus on achieving profitable revenue growth and strict management of operating expenses. 1 Full year 2020 net sales are estimated to increase, and operating loss is expected to decrease in comparison to year 2019
Slide 11: Nexstim has a unique proprietary neuronavigated TMS technology
Nexstim has a unique proprietary neuronavigated TMS technology that delivers best in class mapping and treatment for patients with brain diseases and disorders. We are well positioned to a disruptive shift in depression treatment and therapy delivery. With improving economics, driven by record reven
Slide 12: Thank you!
Thank you! Nexstim Plc Public Presentation 12